N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=32 A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Volunteers · Healthy
Primary: Adverse Events — 1; 2; 3; 2 Participants
Phase 1 N=24 Ascending Doses of Autologous FDP vs FFP
Freeze Dried Plasma in Healthy Volunteers
Primary: Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests — 4; 4; 4; 4 Participants
Phase 1 N=170 Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Blood Donors
Primary: Red Blood Cell Post-filtration Recovery — 92.57; 92.70; 90.96; 90.23 % recovery at day 0
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Phase 2 N=651 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
Smallpox
Primary: ELISA GMT — 875.1; 1099.6 Titer
Phase 1 N=16 Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
Malaria,Falciparum · Parasitemia · Protozoan Infections
Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence
Phase 1 N=64 A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Measured Serum Concentration (Cmax) for Serum Deferiprone and Deferiprone 3-O-glucuronide — 7.406; 17.835; 27.749; 36.644 μg/mL
Phase 4 N=50 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
Phase 2 N=15 In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
Healthy
Primary: Post Infusion Recovery of Test Platelets at End of Storage (Day 7) — 39.5; 57.8; 39.1; 60.4 percentage of infused platelets
Phase 1 N=25 A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
Safety and Tolerability
Primary: Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions — 1; 2; 3; 2 Participants
Phase 1 N=29 Inactivation of Whole Blood With Mirasol
Focus of Study: Radiolabel Recovery and Survival of RBCs
Primary: Red Blood Cell (RBC) 24-Hour Recovery — 82.51; 91.70 % 24-hour RBC Recovery
Phase 1 N=28 Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets
Thrombocytopenia
Primary: Adverse Events (AEs) by Level of Severity — 8; 18; 6; 21 adverse events
Phase 1 N=64 Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers
Healthy
Primary: Adverse Events That Meet Dose-limiting Toxicity Criteria Specified in Protocol. — 0; 0; 0; 0 participants
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
Phase 1 N=56 Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
Healthy
Primary: Safety and Tolerability Assessments by Vital Signs — 3; 3; 6; 6 Participants
Phase 3 N=420 Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
Bleeding Cardiac Surgery Patients
Primary: Number of Patients Requiring Additional Hemostatic Intervention — 166; 125; 47; 82 Participants — p=<0.0001
Phase 2 N=223 Plasma Therapy of COVID-19 in Severely Ill Patients
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
N/A N=3,443 IMPACT (Improving Plasma Collection) Clinical Trial
Apheresis Related Hypotension
Primary: Rate of Significant Hypotensive Adverse Events — .035; .051 % of significant hypotensive AEs
Phase 3 N=1,129 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
Smallpox
Primary: Vaccinia-Specific Neutralizing Antibodies Measured by Plaque Reduction Neutralization Test (PRNT) — 252.7; 269.9; 242.0 Titer
Phase 2 N=200 Cold Stored Platelet in Hemorrhagic Shock
Trauma · Hemorrhage
Primary: Study Feasibility — 91; 82 Participants
Phase 1 N=64 Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
Healthy
Primary: Number of Participants With Adverse Events (AEs) — 0; 0; 1; 1 Participants
Phase 1 N=20 Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers
Healthy
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 8.05; 8.21; 7.43; 16.71 μg/mL
Phase 1 N=41 Anthrax AV7909 Liquid vs Lyophilized
Anthrax · Anthrax Immunisation
Primary: Number of Participants With Serious Adverse Events (SAEs). — 0; 0 Participants
N/A N=31 The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity
Extracorporeal Membrane Oxygenation
Primary: ECMO Pump Longevity — 187; 131 hours — p=0.39
Phase 2 N=20 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs
Phase 1 N=16 Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Abnormal Physical Exam Findings — 0; 0; 0 Participants
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
Phase 2 N=30 Convalescent Plasma for Patients With COVID-19
Coronavirus Infection · Coronavirus · COVID
Primary: Change in Respiratory Disease Severity — 251; 276 ratio
N/A N=254 Frozen Red Blood Cell Transfusions in Trauma Patients
Blood Loss · Anemia · Trauma
Primary: Tissue Oxygenation — 100.3; 98.2; 98.3 percentage of baseline